Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis
Shixue Chen(Chinese PLA General Hospital), Yi Hu(Chinese PLA General Hospital), Zhefeng Liu(Chinese People's Liberation Army), Zhaozhen Wu(Nankai University), Haitao Tao(Chinese People's Liberation Army), Sujie Zhang(Chinese People's Liberation Army), Zhibo Zhang(Chinese PLA General Hospital), Jinliang Wang(Chinese PLA General Hospital), Ziwei Huang(Nanjing University of Chinese Medicine), Pengfei Cui(Chinese PLA General Hospital), Yuanyu Qian(Chinese People's Liberation Army), Xuan Zheng(Jinan University), Junxun Ma(Chinese People's Liberation Army), Di Huang(Qilu Hospital of Shandong University)
Cited by 125
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias
|Molecular Cancer Therapeutics|2006|186
Structural and Functional Characterization of Human CXCR4 as a Chemokine Receptor and HIV-1 Co-receptor by Mutagenesis and Molecular Modeling Studies
|Journal of Biological Chemistry|2001|138
Bio-template synthesis of Mo-doped polymer carbon nitride for photocatalytic hydrogen evolution
|Applied Catalysis B: Environmental|2019|133
Exploring the Stereochemistry of CXCR4-Peptide Recognition and Inhibiting HIV-1 Entry with d-Peptides Derived from Chemokines
|Journal of Biological Chemistry|2002|117